Online citations, reference lists, and bibliographies.
← Back to Search

A Systematic Review Of Extrapleural Pneumonectomy For Malignant Pleural Mesothelioma

C. Cao, T. Yan, P. Bannon, B. McCaughan
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction: The primary objective of the present systematic review was to evaluate the safety and efficacy of extrapleural pneumonectomy (EPP) for patients with malignant pleural mesothelioma. Methods: A systematic review of relevant studies identified through five online search databases was performed. Two reviewers independently appraised each study. Results: Thirty-four of 58 relevant studies from 26 institutions containing the most updated data were evaluated for survival and perioperative outcomes after EPP. The median overall survival varied from 9.4 to 27.5 months, and 1-, 2-, and 5-year survival rates ranged from 36 to 83%, 5 to 59%, and 0 to 24%, respectively. Overall perioperative mortality rates ranged from 0 to 11.8%, and the perioperative morbidity rates ranged from 22 to 82%. Quality of life assessments from three studies reported improvements in nearly all domains at 3 months postoperatively. Patients who underwent trimodality therapy involving EPP and adjuvant chemoradiotherapy had a median overall survival of 13 to 23.9 months. Discussions: The current evidence suggests that selected patients with malignant pleural mesothelioma may benefit from EPP, especially when combined with neoadjuvant or adjuvant chemotherapy and adjuvant radiotherapy.
This paper references
10.1016/J.ATHORACSUR.2007.06.066
Malignant pleural mesothelioma: surgical management in 285 patients.
P. Schipper (2008)
10.1016/S1010-7940(02)00273-7
The management of malignant pleural mesothelioma; single centre experience in 10 years.
T. Aziz (2002)
10.1016/J.EJCTS.2007.01.061
Right extrapleural pneumonectomy for malignant mesothelioma via median sternotomy or thoracotomy? Short- and long-term results.
J. Edwards (2007)
10.1510/ICVTS.2007.166322
Radical surgery for malignant pleural mesothelioma: results and prognosis.
M. Okada (2008)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.1007/S00268-003-7159-5
Radical Surgery for Mesothelioma: How Can We Obtain Evidence?
T. Treasure (2003)
10.1016/S1010-7940(02)00735-2
The management of malignant pleural mesothelioma.
G. Maggi (2003)
10.1097/JTO.0b013e3181ae26ae
The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study
T. Treasure (2009)
10.1016/S1010-7940(01)00594-2
Trimodality management of malignant pleural mesothelioma.
G. Maggi (2001)
10.1007/BF02306613
Surgically debulked malignant pleural mesothelioma: Results and prognostic factors
H. Pass (2006)
10.1002/cncr.24108
A possible association between aprotinin and improved survival after radical surgery for mesothelioma
P. Norman (2009)
10.1016/j.lungcan.2008.01.013
Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes.
K. Ribi (2008)
10.1016/S0022-5223(98)70274-0
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
H. Pass (1998)
10.1200/JCO.2004.10.071
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
5-year prospective results of trimodality treatment for malignant pleural mesothelioma.
V. Pagan (2006)
10.1016/S0022-5223(19)36578-X
Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma.
D. Sugarbaker (1991)
10.1378/CHEST.103.4_SUPPLEMENT.373S
Natural history and epidemiology of malignant mesothelioma.
K. Antman (1993)
10.1136/oem.2006.031823
Projected mesothelioma incidence in men in New South Wales
M. Clements (2007)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1016/J.EJCTS.2007.01.064
Case-control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma.
A. Martin-Ucar (2007)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.1378/CHEST.103.4_SUPPLEMENT.377S
Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma.
D. Sugarbaker (1993)
10.1016/j.ejcts.2008.03.003
Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
C. Aigner (2008)
10.1016/j.athoracsur.2007.11.065
Risk factors for major complications after extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2008)
10.1016/j.athoracsur.2008.01.088
The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma.
T. Mineo (2008)
10.1016/S0022-5223(96)70342-2
The importance of surgical staging in the treatment of malignant pleural mesothelioma.
V. Rusch (1996)
10.1136/thx.4.4.173
Extrapleural Pneumonectomy and Pleurectomy in Pulmonary Tuberculosis *
I. A. Sarot (1949)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.1200/JCO.1996.14.3.1007
Chemotherapy in malignant pleural mesothelioma. A review.
S. T. Ong (1996)
10.1016/j.athoracsur.2009.01.026
Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma.
T. Yan (2009)
10.1016/S1010-7940(03)00376-2
Treatment of mesothelioma in Bloemfontein, South Africa.
W. de Vries (2003)
10.1097/JTO.0b013e31816fca1b
Trimodality Treatment of Malignant Pleural Mesothelioma
H. Batırel (2008)
10.1016/S0003-4975(96)01228-3
Patterns of failure after trimodality therapy for malignant pleural mesothelioma.
E. Baldini (1997)
10.1016/J.ATHORACSUR.2004.01.034
The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma.
D. Stewart (2004)
10.1016/J.JTCVS.2007.02.014
Ten traps for the unwary in surgical series: a case study in mesothelioma reports.
T. Treasure (2007)
10.1097/00000658-199609000-00005
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
D. Sugarbaker (1996)
10.1016/J.JTCVS.2006.06.044
Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2007)
10.1016/S0022-5223(19)36577-8
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
10.1016/1010-7940(91)90142-7
Diagnostic and therapeutic strategy in malignant pleural mesothelioma.
D. Branscheid (1991)
10.1016/S0169-5002(00)00152-5
Surgical approach to pleural diffuse mesothelioma in Japan.
K. Takagi (2001)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/J.JTCVS.2005.11.044
The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma.
J. Edwards (2006)
10.1016/J.EJCTS.2006.01.015
Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
I. Opitz (2006)
10.1016/J.ATHORACSUR.2007.04.076
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1200/JCO.1989.7.8.1157
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
P. Ruffié (1989)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1016/S0003-4975(10)64593-6
Extrapleural pneumonectomy for diffuse, malignant mesothelioma.
M. Davalle (1986)
10.1016/j.jtcvs.2008.07.055
A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
L. Zellos (2009)
10.1016/j.athoracsur.2009.05.036
Trimodality therapy for malignant pleural mesothelioma.
G. Buduhan (2009)
10.1016/J.EJCTS.2004.12.028
Extra-pleural pneumonectomy for malignant pleural mesothelioma: the risks of induction chemotherapy, right-sided procedures and prolonged operations.
D. Stewart (2005)
Incidence of atrial Journal of Thoracic Oncology
S Neragi-Miandoab (2010)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1097/JTO.0b013e3181ae25bf
Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia
A. Hasani (2009)
10.1093/OXFORDJOURNALS.AJE.A009093
Analysis of current trends in United States mesothelioma incidence.
B. Price (1997)
10.1016/j.athoracsur.2009.04.038
Placenta growth factor expression has prognostic value in malignant pleural mesothelioma.
E. Pompeo (2009)
10.1245/s10434-008-9899-9
Surgical Treatment in the Management of Malignant Pleural Mesothelioma: A Single Institution’s Experience
J. Sandick (2008)
10.1007/BF00175403
A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study
B. Zidar (2004)
10.1016/j.jtcvs.2008.12.045
Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors.
T. Yan (2009)
10.1097/JTO.0b013e31815608d9
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
10.1510/icvts.2008.181099
Incidence of atrial fibrillation after extrapleural pneumonectomy vs. pleurectomy in patients with malignant pleural mesothelioma.
S. Neragi-Miandoab (2008)
10.1016/J.LUNGCAN.2007.02.004
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
F. Rea (2007)
10.1309/AJCPHV33LJTVDGJJ
Histologic assessment and prognostic factors of malignant pleural mesothelioma treated with extrapleural pneumonectomy.
A. Arrossi (2008)
10.1002/1097-0142(19831201)52:11<1981::AID-CNCR2820521102>3.0.CO;2-P
Malignant mesothelioma. The eastern cooperative oncology group (ECOG) experience
H. Lerner (1983)
10.1016/J.LUNGCAN.2004.11.003
Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary.
D. Maziak (2005)
10.1007/s00268-003-7159-5
Radical Surgery for Mesothelioma: How Can We Obtain Evidence?
M. S. Tom Treasure M.D. (2003)
10.1016/j.jtcvs.2008.02.069
The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
R. Flores (2008)
10.1378/CHEST.120.4.1167
Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results.
H. Schouwink (2001)
10.1097/00130404-200311000-00008
Promising Early Local Control of Malignant Pleural Mesothelioma Following Postoperative Intensity Modulated Radiotherapy (IMRT) to the Chest
A. Ahamad (2003)
10.1016/0003-4975(94)91692-6
1986: Extrapleural pneumonectomy for diffuse, malignant mesothelioma. Updated in 1994.
L. Faber (1994)
10.1002/jso.21261
Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma
V. Ambrogi (2009)
10.1016/S0140-6736(04)17108-0
Pleural mesothelioma: little evidence, still time to do trials
T. Treasure (2004)
10.1016/S0003-4975(99)01038-3
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
V. Rusch (1999)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1016/J.IJROBP.2007.02.047
Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy.
A. Allen (2007)
10.1016/j.jtcvs.2009.02.046
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
T. R. Tilleman (2009)
10.1016/j.ejcts.2009.04.044
Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies.
D. Trousse (2009)
10.1111/j.1445-2197.2009.05060.x
Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy *
J. Alvarez (2009)



This paper is referenced by
10.1378/chest.11-3204
Postmortem findings of malignant pleural mesothelioma: a two-center study of 318 patients.
Rhian S Finn (2012)
10.1007/S00761-014-2886-9
Pleuramesotheliome: Multimodales Management als klinische Herausforderung
Rudolf A. Hatz (2015)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.1097/JTO.0b013e3182199819
Intensity-Modulated Radiotherapy After Extrapleural Pneumonectomy in the Combined-Modality Treatment of Malignant Pleural Mesothelioma
A. Chi (2011)
10.1155/2014/817203
Surgical Management of Malignant Pleural Mesothelioma: Impact of Surgery on Survival and Quality of Life—Relation to Chemotherapy, Radiotherapy, and Alternative Therapies
S. Papaspyros (2014)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.21037/shc-20-64
The role of extrapleural pneumonectomy for malignant pleural mesothelioma: reviewing 20-years of experience
Raphael Werner (2020)
10.1097/JTO.0b013e31822e295a
Miliary mesothelioma: a new clinical and radiological presentation in mesothelioma patients with prolonged survival after trimodality therapy.
L. Purek (2011)
10.1183/09031936.00207213
Multimodal management of malignant pleural mesothelioma: where are we today?
P. V. Van Schil (2014)
10.12998/wjcc.v7.i23.4036
In-vitro proliferation assay with recycled ascitic cancer cells in malignant pleural mesothelioma: A case report
T. Anayama (2019)
10.1038/bjc.2014.478
Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales
A. Linton (2014)
10.4172/2155-9619.S2-011
Malignant Pleural Mesothelioma: Management and Role of Radiation Therapy
Donato (2013)
10.1007/s10405-014-0857-x
Keine Vorteile durch VAT-PP gegenüber der klassischen Talkum-Pleurodese im palliativen Setting
P. Zardo (2014)
10.1016/j.ajpath.2012.12.028
New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.
B. Mossman (2013)
10.5772/47880
Neoadjuvant Chemotherapy in Malignant Pleural Mesothelioma
G. Pasello (2012)
10.1016/j.lungcan.2020.05.032
Addition of radiotherapy to surgery and chemotherapy improves survival in localized malignant pleural mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) study.
Andrew B Thompson (2020)
10.1136/esmoopen-2019-000669
How I treat malignant pleural mesothelioma
G. Viscardi (2020)
10.1016/j.molonc.2014.11.007
MiR‐Score: A novel 6‐microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma
M. Kirschner (2015)
10.1093/annonc/mds537
Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
Y. Tsutani (2013)
10.1016/B978-1-4377-1560-6.00058-5
Lung, Chest Wall, Pleura, and Mediastinum
J. Putnam (2012)
10.1016/S1241-8226(12)50101-5
Traitement chirurgical du mésothéliome pleural
Nicolas Vénissac (2012)
10.3978/j.issn.2072-1439.2015.11.15
Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy.
T. Tagawa (2015)
10.1093/ejcts/ezu001
Surgery for malignant pleural mesothelioma: why we need controlled trials.
T. Treasure (2014)
Data from the AustrianMesothelioma Interest Group (AMIG) database
T. Klikovits (2016)
10.1111/1759-7714.12008
Role of new radiation techniques in the treatment of pleural mesothelioma
M. Amichetti (2013)
10.1097/RCT.0000000000000174
Use of Computed Tomography and Positron Emission Tomography/Computed Tomography for Staging of Local Extent in Patients With Malignant Pleural Mesothelioma
T. Frauenfelder (2015)
10.1007/s00508-016-1037-2
Management of malignant pleural mesothelioma – part 3
T. Klikovits (2016)
Consensus of the AustrianMesothelioma Interest Group (AMIG)
C. Geltner (2016)
10.1136/thoraxjnl-2013-203846
Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position
A. Datta (2013)
10.13032/TJOP.2052-5931.100120
The Role of Surgery in Malignant Pleural Mesothelioma
Levon Toufektzian (2015)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1097/JTO.0000000000000661
A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years’ Experience
I. Opitz (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar